Ocugen, Inc.

According to the Complaint, the Company made false and misleading statements to the market. Ocugen’s information submission to the FDA for the development of a COVID-19 vaccine failed to include sufficient data to support an Emergency Use Authorization (“EUA”). The Company did not submit an EUA to the FDA. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Ocugen, investors suffered damages.

-->

RLX Technology Inc.

According to the Complaint, the Company made false and misleading statements to the market. RLX misstated and omitted facts in its offering documents related to its exposure to the Chinese government’s campaign to create a national standard for e-cigarettes that would bring them in line with traditional tobacco products such as cigarettes. The Company’s financials were not as strong as the offering documents projected and were not indicative of future performance. Based on these facts, the offering documents were false and materially misleading. When the market learned the truth about RLX, investors suffered damages.

-->

AcelRx Pharmaceuticals, Inc.

According to the Complaint, the Company made false and misleading statements to the market. AcelRX failed to maintain appropriate controls over disclosure and marketing of its lead product candidate, DSUVIA. The Company made false and misleading claims about the efficacy and associated risks of DSUVIA in its marketing and advertisements. This led to a heightened risk of regulatory enforcement action against the Company. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about AcelRX, investors suffered damages.

-->

Frequency Therapeutics, Inc.

According to the Complaint, the Company made false and misleading statements to the market. Frequency’s development efforts of its hearing loss treatment titled “FX-322” were not successful. The reality of FX-322’s ongoing clinical study did not match the Company’s positive portrayal. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Frequency, investors suffered damages.

-->

Virgin Galactic Holdings, Inc.

According to the Complaint, the Company made false and misleading statements to the market. Virgin Galactic improperly accounted for outstanding warrants for Social Capital Hedosophia Holdings Corp. (“SCH”). The Company should have treated the warrants as liabilities rather than equities for accounting purposes. The Company failed to maintain appropriate controls over financial reporting. Based on these facts, the Company’s public statements were false and materially misleading. When the market learned the truth about Virgin Galactic, investors suffered damages.

-->

Provention Bio, Inc.

According to the Complaint, the Company made false and misleading statements to the market. Provention’s Biologics License Application (“BLA”) for teplizumab was deficient and would require additional submitted data to secure FDA approval. The teplizumab BLA lacked the strong evidence and support that the Company led the market to believe it had. The Company overstated the chances of the teplizumab BLA being approved and its commercial timeline. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Provention, investors suffered damages.

-->

Washington Prime Group Inc.

According to the Complaint, the Company made false and misleading statements to the market. WPG suffered from a substantially deteriorating financial condition. The Company’s worsening financial condition resulted in considerable uncertainty about its ability to meet capital structure obligations. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about WPG, investors suffered damages.

-->

Ubiquiti Inc.

According to the Complaint, the Company made false and misleading statements to the market. Ubiquiti downplayed the data breach it suffered in January 2021. The hackers had in fact gained administrative access to the Company’s servers, which in turn gave them access to all databases, user credentials, and information needed to force single sign-on cookies. This level of access let attackers remotely access systems belonging to the Company’s clients. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Ubiquiti, investors suffered damages.

-->

Dapper Labs, Inc. – NBA Top Shot Moments

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Dapper Labs, Inc. – NBA Top Shot Moments (“Dapper Labs” or “the Company”) for violations of the federal securities laws.

-->

Danimer Scientific, Inc.

According to the Complaint, the Company made false and misleading statements to the market. Danimer failed to maintain effective internal controls. The Company mischaracterized the size of its operations and its regulatory compliance. The Company overstated the biodegradability of its Nodax product in both landfills and the ocean. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Danimer, investors suffered damages.

-->